Junlin Zhong

Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta-analysis: CEUS Versus CECT for Hepatocellular Carcinoma After TACE

This study reviewed the literature to directly evaluate the diagnostic performance of contrast‐enhanced ultrasonography (CEUS) versus contrast‐enhanced computed tomography (CECT) for assessing residual tumors of hepatocellular carcinoma treated with transarterial chemoembolization.

GW24-e0052 Rosuvastatin inhibits the up-regulation of inflammatory factors of endothelial outgrowth cell induced by C-reactive protein

Objectives To study the effects of rosuvastatin on C reactive protein (CRP)-induced inflammatory factors expression in endothelial outgrowth cells (EOCs). Methods Mononuclear cells (MNCs) were isolated from human umbilical cord blood by density gradient centrifugation. EOCs were treated with CRP of different concentrations (5, 10, 25, 50 ug/mL) and were exposed to 50 ug/mL CRP for different treating time (0, 3, 6, 12 h). Also, EOCs were incubated with rosuvastatin of different concentrations (10-8 M, 10-7 M, 10-6 M) 12 h and then stimulated with 50 ug/mL CRP. The mRNA levels of IL-8, MCP-1, VCAM-1, ICAM-1 of EOCs were measured by quantitative PCR and MCP-1, VCAM-1 protein expressions were tested by ELISA. Results (1) The mRNA levels of inflammatory factors (IL-8, MCP-1, VCAM-1, ICAM-1) and protein levels of (MCP-1, VCAM-1) increased in a dose-dependent manner respectively. (2) The mRNA levels of (IL-8, VCAM-1, ICAM-1)from 50 ug/mL CRP- stimulated cells reached the peak at 6h, while MCP-1 at 3 h; and the protein levels of (MCP-1, VCAM-1) increased in a time-dependent manner. (3) The mRNA and protein level of the inflammatory factors were significantly decreased by rosuvastatin with different dosages. Conclusions CRP with different doses and different treating time induced the inflammation response of EOCs, which further proved CRP was not just an inflammatory marker, and rosuvastatin could attenuate CRP-induced inflammatory response of EOCs, which provided new targets for the prevention of atherosclerosis.